Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetirizine for Adverse Effects of ALA-PDT in Actinic Keratosis
NCT02451579Completed
- Sponsor
- Cosmetic Laser Dermatology
- Start
- Feb 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in actinic keratosis (AK) comparing Cetirizine Hydrochloride with Placebo (2 arms). Primary endpoint: Localized Skin Response at 180 days. Started Feb 2015; status: completed.
02
Drugs
cetirizine
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02451579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451579.